Table 3.
Indications for the use of platelet inhibitors.
| Antiplatelet indication |
Overall N = 298 |
Acetylsalicylic acid (ASA) N = 246a |
Clopidogrel N = 19a |
Dipyridamol N = 7a |
Dual antiplatelet therapyb N = 26a |
|---|---|---|---|---|---|
| Secondary prophylaxis (coronary disease/PVDc) | 129 (43%) | 106 (43%) | 5 (26%) | 1 (14%) | 17 (65%) |
| Secondary prophylaxis (Stroke/TIAd) | 81 (27%) | 54 (22%) | 13 (68%) | 6 (86%) | 8 (31%) |
| Primary prophylaxis | 47 (16%) | 47 (19%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Other | 14 (4.7%) | 12 (4.9%) | 1 (5.3%) | 0 (0%) | 1 (3.8%) |
| (Missing) | 27 (9.1%) | 27 (11%) | 0 (0%) | 0 (0%) | 0 (0%) |
a
Statistics presented: n (%).
b
ASA + clopidogrel, dipyridamol, tikagrelor, or prasugrel.
c
PVD, peripheral vascular disease.
d
TIA, transient ischemic attack.